CO5721001A2 - Derivados sustituidos de morfolina y tiomorfolina - Google Patents
Derivados sustituidos de morfolina y tiomorfolinaInfo
- Publication number
- CO5721001A2 CO5721001A2 CO06091597A CO06091597A CO5721001A2 CO 5721001 A2 CO5721001 A2 CO 5721001A2 CO 06091597 A CO06091597 A CO 06091597A CO 06091597 A CO06091597 A CO 06091597A CO 5721001 A2 CO5721001 A2 CO 5721001A2
- Authority
- CO
- Colombia
- Prior art keywords
- cycloalkyl
- ilo
- alky
- halo
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
1.- Un derivado sustituido de morfolina o tiomorfolina de formula general Ien el cualq es 0 o 1;W es O o S;X es CO;Z es O;R1 se selecciona del grupo formado por halogeno, ciano, alqu(en/in)iIo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)iIo C3-8-alqu(en/in)iIo C1-6, halo-alqu(en/in)iIo C1-6, halo-cicloalqu(en)iIo C3-8, halo-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, alqu(en/in)iIoxi C1-6, cicloalqu(en)iloxi C3-8 y cicloalqu(en)ilo C3-8-alqu(en/in)iIoxi C1-6;R2 se selecciona del grupo formado por halogeno, ciano, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, halo-alqu(en/in)ilo C1-6, halo-cicloalqu(en)ilo C3-8, halo-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, alqu(en/in)iloxi C1-6, cicloalqu(en)iloxi C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)iIoxi C1-6, el fenilo sustituido en forma opcional y el piridilo sustituido en forma opcional; en los que el fenilo y el piridilo estan sustituidos en forma opcional con uno o mas sustituyentes que son, en forma independiente, halogeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8 o cicloalqu(en)iIo C3-8-alqu(en/in)ilo C1-6;R3 se selecciona del grupo formado por alqu(en/in)ilo C1-10, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, Ar-alqu(en/in)ilo C1-6, Ar-cicloalqu(en)ilo C3-8, Ar-cicloalqu(en)ilo C3-8-alqu(en/in)iIo C1-6 y Ar; ycada uno de R4, R5, R6 y R7 se selecciona en forma independiente del grupo formado por hidrogeno y Ar;como base libre o sus sales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200400412 | 2004-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5721001A2 true CO5721001A2 (es) | 2007-01-31 |
Family
ID=37730781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06091597A CO5721001A2 (es) | 2004-03-12 | 2006-09-12 | Derivados sustituidos de morfolina y tiomorfolina |
Country Status (32)
Country | Link |
---|---|
US (6) | US7501414B2 (es) |
EP (3) | EP1727809B8 (es) |
JP (1) | JP5006184B2 (es) |
KR (2) | KR20120136422A (es) |
CN (2) | CN1930138A (es) |
AR (1) | AR049784A1 (es) |
AT (2) | ATE398112T1 (es) |
AU (1) | AU2005221762B2 (es) |
BR (1) | BRPI0508570B8 (es) |
CA (1) | CA2559397C (es) |
CO (1) | CO5721001A2 (es) |
CY (2) | CY1110392T1 (es) |
DE (2) | DE602005016849D1 (es) |
DK (2) | DK1727809T3 (es) |
EA (1) | EA015120B1 (es) |
EG (1) | EG25344A (es) |
ES (2) | ES2306087T3 (es) |
HK (1) | HK1172618A1 (es) |
HR (1) | HRP20090685T1 (es) |
IL (1) | IL177859A (es) |
MY (2) | MY147786A (es) |
NO (1) | NO337161B1 (es) |
NZ (1) | NZ549133A (es) |
PL (2) | PL1947093T3 (es) |
PT (2) | PT1947093E (es) |
RS (2) | RS50606B (es) |
SG (1) | SG151254A1 (es) |
SI (2) | SI1947093T1 (es) |
TW (2) | TWI349666B (es) |
UA (2) | UA102517C2 (es) |
WO (1) | WO2005087754A1 (es) |
ZA (2) | ZA200607286B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7799832B2 (en) | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
TWI349666B (en) * | 2004-03-12 | 2011-10-01 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivatives |
UA89503C2 (uk) * | 2004-09-13 | 2010-02-10 | Х. Луннбек А/С | Заміщені похідні аніліну |
JP5237643B2 (ja) * | 2005-03-03 | 2013-07-17 | ハー・ルンドベック・アクチエゼルスカベット | 置換されたピリジン誘導体 |
UA92340C2 (en) * | 2005-03-03 | 2010-10-25 | Х. Луннбек А/С | Substituted pyridine derivatives |
BRPI0707495A2 (pt) * | 2006-02-07 | 2011-05-03 | H Lundbeck & Co As | método para tratar ou reduzir os sintomas de esquizofrenia, uso de um abridor seletivo de canal de potássio kcnq, método de triagem de um composto, e, uso de um composto |
US7960436B2 (en) | 2006-06-05 | 2011-06-14 | Valeant Pharmaceuticals International | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators |
PL2061465T3 (pl) | 2006-08-23 | 2014-03-31 | Valeant Pharmaceuticals Int | Pochodne 4-(N-azacykloalkilo) anilidów jako modulatory kanałów potasowych |
US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
NZ577740A (en) | 2006-11-28 | 2012-06-29 | Valeant Pharmaceuticals Int | 1,4 diamino bicyclic retigabine analogues as potassium channel modulators |
WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
US8367684B2 (en) | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
WO2009015667A1 (en) * | 2007-08-01 | 2009-02-05 | H. Lundbeck A/S | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
SG176464A1 (en) * | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
WO2010094644A1 (en) * | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
WO2010094645A1 (en) * | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
TW201041857A (en) * | 2009-05-11 | 2010-12-01 | Lundbeck & Co As H | Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide |
US20100286138A1 (en) * | 2009-05-11 | 2010-11-11 | H. Lundbeck A/S | Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide |
US20120232058A1 (en) * | 2009-09-07 | 2012-09-13 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
KR101449348B1 (ko) | 2010-07-08 | 2014-10-08 | 화이자 인코포레이티드 | Kv7 칼륨 채널 개방제로서의 피페리디닐 피리미딘 아미드 |
CN103073455B (zh) | 2011-10-25 | 2015-08-19 | 中国科学院上海药物研究所 | 一类新型的kcnq钾通道激动剂、其制备方法和用途 |
US9321750B2 (en) * | 2012-04-20 | 2016-04-26 | Innov17 Llc | ROR modulators and their uses |
CN103044431A (zh) * | 2012-10-22 | 2013-04-17 | 中国药科大学 | 制备五氟磺草胺的新方法 |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US20170360726A1 (en) * | 2014-12-05 | 2017-12-21 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
EP3366683A1 (en) * | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Cyclic amides, acteamides and ureas useful as potassium channel openers |
WO2020157126A1 (en) | 2019-01-29 | 2020-08-06 | Università degli Studi di Salerno | Modulators of potassium ion channels and uses thereof |
IL282188A (en) * | 2021-04-08 | 2022-11-01 | Yeda Res & Dev | Combined use of ketamine and bretigabine for the treatment of psychiatric disorders |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03175086A (ja) * | 1989-09-14 | 1991-07-30 | Fuji Photo Film Co Ltd | ジアゾ感熱記録材料 |
DE4200259A1 (de) | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
DE19539861A1 (de) | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
NZ329200A (en) * | 1996-12-16 | 1999-05-28 | Hoechst Ag | Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
PL334250A1 (en) | 1996-12-23 | 2000-02-14 | Du Pont Pharm Co | Nitrogen containing hetero-aromatic compounds and inhibitors of xa factor |
JP2001506271A (ja) * | 1996-12-23 | 2001-05-15 | デュポン ファーマシューティカルズ カンパニー | Xa因子阻害剤としての酸素またはイオウを含む複素環式芳香族化合物 |
CA2314401A1 (en) | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
WO1999050255A2 (en) | 1998-03-27 | 1999-10-07 | Du Pont Pharmaceuticals Company | Disubstituted pyrazolines and triazolines as factor xa inhibitors |
NZ516743A (en) * | 1999-08-04 | 2004-02-27 | Icagen Inc | Methods for treating or preventing pain and anxiety |
US6495550B2 (en) * | 1999-08-04 | 2002-12-17 | Icagen, Inc. | Pyridine-substituted benzanilides as potassium ion channel openers |
US6117900A (en) | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
AU2001263486A1 (en) | 2000-05-26 | 2001-12-11 | Bristol-Myers Squibb Company | Human KCNQ5 potassium channel, methods and compositions thereof |
WO2001096540A2 (en) | 2000-06-11 | 2001-12-20 | Dupont Pharmaceuticals Company | Hepatitis c protease exosite for inhibitor design |
PE20020044A1 (es) * | 2000-06-16 | 2002-01-30 | Upjohn Co | Tiazina oxazolidinona |
US6589986B2 (en) * | 2000-12-20 | 2003-07-08 | Wyeth | Methods of treating anxiety disorders |
IL156601A0 (en) * | 2001-01-16 | 2004-01-04 | Astrazeneca Ab | Therapeutic chroman compounds |
JP2004517129A (ja) * | 2001-01-16 | 2004-06-10 | アストラゼネカ・アクチエボラーグ | 治療用クロモン化合物 |
CN1250519C (zh) * | 2001-01-19 | 2006-04-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 具有调节钾通道功能的胺衍生物及其制备方法和应用 |
MXPA03007395A (es) * | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Derivados de pirimidin-5-carboxamida 2,4-disustituida como moduladores del canal de potasio kcnq. |
SE0103649D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinoline compounds |
SE0103648D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinolone compounds |
TWI349666B (en) * | 2004-03-12 | 2011-10-01 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivatives |
-
2005
- 2005-03-03 TW TW094106488A patent/TWI349666B/zh not_active IP Right Cessation
- 2005-03-03 TW TW096141845A patent/TWI357901B/zh not_active IP Right Cessation
- 2005-03-08 AR ARP050100893A patent/AR049784A1/es active IP Right Grant
- 2005-03-09 JP JP2007502191A patent/JP5006184B2/ja active Active
- 2005-03-09 AU AU2005221762A patent/AU2005221762B2/en not_active Ceased
- 2005-03-09 DK DK05706819T patent/DK1727809T3/da active
- 2005-03-09 SI SI200530872T patent/SI1947093T1/sl unknown
- 2005-03-09 UA UAA200911734A patent/UA102517C2/ru unknown
- 2005-03-09 BR BRPI0508570A patent/BRPI0508570B8/pt not_active IP Right Cessation
- 2005-03-09 KR KR1020127029156A patent/KR20120136422A/ko not_active Application Discontinuation
- 2005-03-09 PL PL08007169T patent/PL1947093T3/pl unknown
- 2005-03-09 PT PT08007169T patent/PT1947093E/pt unknown
- 2005-03-09 DE DE602005016849T patent/DE602005016849D1/de active Active
- 2005-03-09 AT AT05706819T patent/ATE398112T1/de active
- 2005-03-09 EP EP05706819A patent/EP1727809B8/en active Active
- 2005-03-09 EP EP09170831A patent/EP2138487A1/en not_active Withdrawn
- 2005-03-09 ES ES05706819T patent/ES2306087T3/es active Active
- 2005-03-09 DE DE602005007474T patent/DE602005007474D1/de active Active
- 2005-03-09 ES ES08007169T patent/ES2334076T3/es active Active
- 2005-03-09 EA EA200601686A patent/EA015120B1/ru unknown
- 2005-03-09 SI SI200530344T patent/SI1727809T1/sl unknown
- 2005-03-09 SG SG200901657-7A patent/SG151254A1/en unknown
- 2005-03-09 PL PL05706819T patent/PL1727809T3/pl unknown
- 2005-03-09 AT AT08007169T patent/ATE443702T1/de active
- 2005-03-09 CN CNA2005800078857A patent/CN1930138A/zh active Pending
- 2005-03-09 DK DK08007169.9T patent/DK1947093T3/da active
- 2005-03-09 RS RSP-2008/0412A patent/RS50606B/sr unknown
- 2005-03-09 KR KR1020067018688A patent/KR101411204B1/ko active IP Right Grant
- 2005-03-09 CA CA2559397A patent/CA2559397C/en active Active
- 2005-03-09 WO PCT/DK2005/000159 patent/WO2005087754A1/en active Application Filing
- 2005-03-09 NZ NZ549133A patent/NZ549133A/en not_active IP Right Cessation
- 2005-03-09 EP EP08007169A patent/EP1947093B9/en active Active
- 2005-03-09 PT PT05706819T patent/PT1727809E/pt unknown
- 2005-03-09 CN CN201110328836.0A patent/CN102516204B/zh active Active
- 2005-03-09 RS RSP-2009/0558A patent/RS51066B/sr unknown
- 2005-03-11 MY MYPI20094719A patent/MY147786A/en unknown
- 2005-03-11 MY MYPI20051046A patent/MY143698A/en unknown
- 2005-09-03 UA UAA200610517A patent/UA90670C2/uk unknown
- 2005-12-21 US US11/314,802 patent/US7501414B2/en active Active
-
2006
- 2006-08-31 ZA ZA2006/07286A patent/ZA200607286B/en unknown
- 2006-09-03 IL IL177859A patent/IL177859A/en active IP Right Grant
- 2006-09-12 EG EGNA2006000856 patent/EG25344A/xx active
- 2006-09-12 CO CO06091597A patent/CO5721001A2/es active IP Right Grant
- 2006-10-10 NO NO20064599A patent/NO337161B1/no not_active IP Right Cessation
-
2007
- 2007-11-12 ZA ZA200709718A patent/ZA200709718B/xx unknown
-
2008
- 2008-09-10 CY CY20081100969T patent/CY1110392T1/el unknown
-
2009
- 2009-01-28 US US12/361,404 patent/US20090143369A1/en not_active Abandoned
- 2009-01-28 US US12/361,509 patent/US7632835B2/en not_active Expired - Fee Related
- 2009-11-03 US US12/611,249 patent/US8012962B2/en not_active Expired - Fee Related
- 2009-11-05 US US12/612,727 patent/US7812023B2/en active Active
- 2009-12-21 CY CY20091101325T patent/CY1109656T1/el unknown
- 2009-12-23 HR HR20090685T patent/HRP20090685T1/hr unknown
-
2011
- 2011-07-28 US US13/192,833 patent/US8299075B2/en active Active
-
2012
- 2012-12-27 HK HK12113443.2A patent/HK1172618A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5721001A2 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
CR8264A (es) | Derivados de malonamida bloqueadores de la actividad gamma-secretase | |
RS50537B (sr) | Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii | |
AR077440A1 (es) | Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas | |
AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
AR050620A1 (es) | Derivados de n-2 adamantanil -2- fenoxi- acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide | |
AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
AR049543A1 (es) | Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica | |
CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
AR066606A1 (es) | Compuestos de heteroarilamida pirimidona | |
CO6190521A2 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa | |
PE20120034A1 (es) | Compuestos derivados de n-fenilpirimidin-2-amina | |
CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
CR10509A (es) | Derivados de cinamoil-piperazina y su utilizacion como antagonistas de par-1 | |
NO20071873L (no) | DNA-PK inhibotorer. | |
ATE523566T1 (de) | Kationische imidazolazofarbstoffe mit einer 2,5- diaminophenyleinheit | |
CO5650235A2 (es) | Derivados de imidazol | |
AR065587A1 (es) | Aminoamidas como antagonistas de orexina | |
AR070264A1 (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos | |
AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
AR066603A1 (es) | Derivados de arilamida pirimidona | |
AR050153A1 (es) | Beta-agonistas, procedimiento para su preparacion y su uso como medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |